Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02422654 · ClinicalTrials.gov registry record · Phase 1
Taste Evaluation of Different Liquid Formulations With Eliglustat
A Phase 1 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02422654: Completed Phase 1 study, sponsored by Genzyme, a Sanofi Company.
NCT02422654 is a Phase 1 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02422654, a Phase 1 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Primary Objective: The purpose of this study is to assess the palatability of eliglustat prototype liquid formulations in healthy subjects.
Interventions
- DRUG eliglustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-04 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
What the finished NCT02422654 record still lists
NCT02422654 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which eliglustat is the first listed.
NCT02422654 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02422654 about?
NCT02422654 is a clinical study titled "Taste Evaluation of Different Liquid Formulations With Eliglustat". Primary Objective: The purpose of this study is to assess the palatability of eliglustat prototype liquid formulations in healthy subjects.
What is the current status of trial NCT02422654?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-04. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02422654?
The interventions under investigation include: eliglustat (DRUG).
Who is sponsoring clinical trial NCT02422654?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02422654's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia